Glenmark Pharma launches India's first Triple-Drug Combo for type 2 Diabetes

Glenmark Pharmaceuticals Ltd saw a rise in its shares during morning trading on October 18, following the announcement of its launch of a triple-drug fixed-dose combination (FDC) comprising Teneligliptin, Dapagliflozin, and Metformin. This combination targets type 2 diabetes in adults with comorbidities, making Glenmark the first company in India to introduce this treatment. Taken once daily under prescription, the drug enhances glycemic control in type 2 diabetes patients.

Priced at Rs 14 per tablet, this product is expected to reduce daily therapy costs by 30%. Marketed under the name Zita DM, it contains DPP4 inhibitor Teneligliptin (20mg), SGLT2 inhibitor Dapagliflozin (10mg), and Metformin SR (500mg/1000mg) in a fixed dose.

Alok Malik, President and Business Head – India Formulations at Glenmark Pharma, expressed pride in the introduction of Zita DM. He emphasized that it offers an effective and economical solution for adult patients dealing with high HbA1c levels and other comorbidities, while also reducing significant renal and cardiac adverse events.

Glenmark reported that its Zita line of medicines annually supports approximately 1.75 million type 2 diabetic patients in India. According to IQVIA sales data from the 12 months ending August 2023, the market for oral anti-diabetic drugs in the country is estimated at Rs 12,522 crore, reflecting a 6.5% yearly growth.